Literature DB >> 36253980

High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma.

Can Zhang1, Xinghua Zhu2, Yong Li1, Jia Shao1, Haibo Xu1, Lei Chen1, Youli Dan3, Hua Jin4, Aiqin He1.   

Abstract

Proline-rich tyrosine kinase-2 (PYK2), also known as calcium dependent tyrosine kinase, regulates different signal transduction cascades that control cell proliferation, migration, and invasion. However, the role of PYK2 in cervical cancer remains to be elucidated. The current study retrospectively included 134 patients with cervical cancer from December 2007 to September 2014. PYK2 expression was detected in tissue microarray and cervical cancer cell lines. Statistical analysis was performed to evaluate its clinicopathological significance. Small interfering RNA (siRNA) was employed to suppress endogenous PYK2 expression in cervical cancer cells to observe the biological function. PYK2 expression was up-regulated in cervical cancer specimens compared with paired adjacent normal cervical tissue samples. Statistical analyses indicated that PYK2 expression might be an independent prognostic indicator for patients with early-stage cervical cancer. A nomogram model was constructed based on PYK2 expression and other clinicopathological risk factors, and it performed well in predicting patients survival. In cellular studies, down-regulation of PYK2 remarkably inhibited cellular proliferation, migration and invasion. PYK2 expression possessed the potential to serve as a novel prognostic marker in cervical cancer patients.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 36253980      PMCID: PMC9575807          DOI: 10.1097/MD.0000000000031178

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


  30 in total

1.  Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration.

Authors:  M Okigaki; C Davis; M Falasca; S Harroch; D P Felsenfeld; M P Sheetz; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

2.  Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.

Authors:  S Roelle; R Grosse; T Buech; V Chubanov; T Gudermann
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

3.  Inhibition of PYK2-induced actin cytoskeleton reorganization, PYK2 autophosphorylation and focal adhesion targeting by FAK.

Authors:  Q S Du; X R Ren; Y Xie; Q Wang; L Mei; W C Xiong
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

4.  Gonadotropin-releasing hormone functionally antagonizes testosterone activation of the human androgen receptor in prostate cells through focal adhesion complexes involving Hic-5.

Authors:  Stuart Maudsley; Lindsay Davidson; Adam J Pawson; Sarah H Freestone; Rakel López de Maturana; Axel A Thomson; Robert P Millar
Journal:  Neuroendocrinology       Date:  2007-01-04       Impact factor: 4.914

5.  FAK/PYK2 promotes the Wnt/β-catenin pathway and intestinal tumorigenesis by phosphorylating GSK3β.

Authors:  Chenxi Gao; Guangming Chen; Shih-Fan Kuan; Dennis Han Zhang; David D Schlaepfer; Jing Hu
Journal:  Elife       Date:  2015-09-03       Impact factor: 8.140

6.  The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04).

Authors:  Jeanny Kwon; Keun-Young Eom; Young Seok Kim; Won Park; Mison Chun; Jihae Lee; Yong Bae Kim; Won Sup Yoon; Jin Hee Kim; Jin Hwa Choi; Sei Kyung Chang; Bae Kwon Jeong; Seok Ho Lee; Jihye Cha
Journal:  Cancer Res Treat       Date:  2017-10-24       Impact factor: 4.679

7.  Prognostic Role of Squamous Cell Carcinoma Antigen in Cervical Cancer: A Meta-analysis.

Authors:  Zhenhua Liu; Hongtai Shi
Journal:  Dis Markers       Date:  2019-06-02       Impact factor: 3.434

8.  A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.

Authors:  Toshio Shimizu; Kazuya Fukuoka; Masayuki Takeda; Tutomu Iwasa; Takeshi Yoshida; Joanna Horobin; Mitchell Keegan; Lou Vaickus; Ajit Chavan; Mahesh Padval; Kazuhiko Nakagawa
Journal:  Cancer Chemother Pharmacol       Date:  2016-03-30       Impact factor: 3.333

9.  CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.

Authors:  Denis Lane; Isabelle Matte; Claude Laplante; Perrine Garde-Granger; Alex Carignan; Paul Bessette; Claudine Rancourt; Alain Piché
Journal:  Mol Cancer       Date:  2016-09-09       Impact factor: 27.401

10.  PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.

Authors:  Amir Kedan; Nandini Verma; Ashish Saroha; Michal Shreberk-Shaked; Anna-Katharina Müller; Nishanth Ulhas Nair; Sima Lev
Journal:  Cell Death Dis       Date:  2018-09-24       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.